GLP-1 Tirz represents a novel class of dual incretin receptor agonists that simultaneously target both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism has generated significant research interest in the metabolic science community.
Dual Receptor Mechanism
Unlike single-target GLP-1 receptor agonists, GLP-1 Tirz activates both GIP and GLP-1 receptors. GIP receptors are expressed in pancreatic beta cells, adipose tissue, and the central nervous system. GLP-1 receptors are found in the pancreas, brain, heart, and gastrointestinal tract. The simultaneous activation of both pathways is hypothesized to produce complementary and potentially synergistic metabolic effects.
Structural Features
GLP-1 Tirz is a 39-amino acid synthetic peptide based on the native GIP sequence with modifications that confer GLP-1 receptor activity. Key structural features include a C20 fatty diacid moiety that enables albumin binding and extends the half-life, amino acid substitutions that provide dual receptor affinity, and engineered resistance to DPP-4 enzymatic degradation.
Preclinical Research Areas
Current research with GLP-1 Tirz spans several domains:
- Metabolic Studies: Investigating effects on glucose homeostasis, insulin sensitivity, and lipid metabolism in animal models
- Body Composition: Examining changes in fat mass distribution and lean body mass preservation
- Receptor Pharmacology: Characterizing binding affinities, signaling bias, and downstream pathway activation
- Comparative Studies: Evaluating dual agonism versus single-target approaches in preclinical models